Clinical trial
Use of Lenalidomide (Revlimid®) in Combination With Dexamethasone in Untreated Non-transplantable Multiple Myeloma in Practice
NCT03001804 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Use of Lenalidomide (Revlimid®) in Combination With Dexamethasone in Untreated Non-transplantable Multiple Myeloma in Practice
- Lead sponsor
- Celgene
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 30, 2017
- Completion date
- December 16, 2022
- Enrollment
- 29 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.